Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer
Authors
Keywords
-
Journal
JNCI-Journal of the National Cancer Institute
Volume 108, Issue 8, Pages djw028
Publisher
Oxford University Press (OUP)
Online
2016-04-14
DOI
10.1093/jnci/djw028
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
- (2015) Nabil Ahmed et al. JOURNAL OF CLINICAL ONCOLOGY
- Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
- (2015) Kurt Schönfeld et al. MOLECULAR THERAPY
- Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy
- (2015) M B Berstad et al. ONCOGENE
- Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer
- (2015) Michael T. Barrett et al. Oncotarget
- Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers
- (2014) Nadine Tung et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen
- (2014) Raffit Hassan et al. CANCER
- Subtyping of triple-negative breast cancer: Implications for therapy
- (2014) Vandana G. Abramson et al. CANCER
- Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells
- (2014) Ho-June Lee et al. CANCER CELL
- Tofacitinib Suppresses Antibody Responses to Protein Therapeutics in Murine Hosts
- (2014) M. Onda et al. JOURNAL OF IMMUNOLOGY
- High EGFR gene copy number predicts poor outcome in triple-negative breast cancer
- (2014) Heae Surng Park et al. MODERN PATHOLOGY
- Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes
- (2014) R. Mazor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Genome-wide siRNA Screen Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple-Negative Breast Cancer Cells
- (2013) Fabio Petrocca et al. CANCER CELL
- Bispecific Antibody to ErbB2 Overcomes Trastuzumab Resistance through Comprehensive Blockade of ErbB2 Heterodimerization
- (2013) B. Li et al. CANCER RESEARCH
- Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
- (2013) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination Treatments with the PKC Inhibitor, Enzastaurin, Enhance the Cytotoxicity of the Anti-Mesothelin Immunotoxin, SS1P
- (2013) Abid R. Mattoo et al. PLoS One
- Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression
- (2013) R. Hassan et al. Science Translational Medicine
- Triple-negative breast cancer: epidemiological considerations and recommendations
- (2012) P. Boyle ANNALS OF ONCOLOGY
- A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
- (2012) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
- (2012) Robert J. Kreitman et al. JOURNAL OF CLINICAL ONCOLOGY
- The clonal and mutational evolution spectrum of primary triple-negative breast cancers
- (2012) Sohrab P. Shah et al. NATURE
- The road to resistance: EGFR mutation and cetuximab
- (2012) Alberto Bardelli et al. NATURE MEDICINE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes
- (2012) W. Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray
- (2011) Donggen Liu et al. MEDICAL ONCOLOGY
- Pseudomonas Exotoxin A-Mediated Apoptosis Is Bak Dependent and Preceded by the Degradation of Mcl-1
- (2010) X. Du et al. MOLECULAR AND CELLULAR BIOLOGY
- ABT-737 Overcomes Resistance to Immunotoxin-Mediated Apoptosis and Enhances the Delivery of Pseudomonas Exotoxin-Based Proteins to the Cell Cytosol
- (2010) R. Traini et al. MOLECULAR CANCER THERAPEUTICS
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Novel Reduced Immunogenicity Bispecific Targeted Toxin Simultaneously Recognizing Human Epidermal Growth Factor and Interleukin-4 Receptors in a Mouse Model of Metastatic Breast Carcinoma
- (2009) S. Oh et al. CLINICAL CANCER RESEARCH
- Induction of programmed cell death in ErbB2/HER2-expressing cancer cells by targeted delivery of apoptosis-inducing factor
- (2009) H. Mahmud et al. MOLECULAR CANCER THERAPEUTICS
- Antibodies specifically targeting a locally misfolded region of tumor associated EGFR
- (2009) T. P. J. Garrett et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
- (2008) Maura N. Dickler et al. BREAST CANCER RESEARCH AND TREATMENT
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More